Gyre Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Gyre Therapeutics, Inc. (GYRE) reported Increase Decrease In Operating Lease Liability of -$536.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$236.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $51.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-12-31 was -$2.24M.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$167.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$744.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$816.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$473.00K.
- Gyre Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$429.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$536.00K 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | -$236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$185.00K derived: sum of 2 quarters · filed 2026-03-13 | -$744.00K 10-K · filed 2026-03-13 | ||
| 2025-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$508.00K 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | -$559.00K 10-Q · filed 2026-08-07 | -$272.00K 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$2.40M derived: sum of 2 quarters · filed 2026-03-13 | -$697.00K derived: sum of 3 quarters · filed 2026-03-13 | -$816.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.54M derived: sum of 2 quarters · filed 2025-11-07 | $1.42M 10-Q · filed 2025-11-07 | $1.31M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.59M 10-Q · filed 2025-08-11 | $1.48M derived: sum of 3 quarters · filed 2025-08-11 | $1.34M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$119.00K 10-Q · filed 2024-05-13 | -$231.00K derived: sum of 2 quarters · filed 2025-03-17 | -$364.00K derived: sum of 3 quarters · filed 2025-03-17 | -$490.00K derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$245.00K derived: sum of 2 quarters · filed 2025-03-17 | -$371.00K derived: sum of 3 quarters · filed 2025-03-17 | -$473.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$259.00K derived: sum of 2 quarters · filed 2024-11-13 | -$361.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$228.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$102.00K 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | -$429.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |